Last updated: February 15, 2026
What Is the Market Position and Price Outlook for NDC 76385-0137?
NDC 76385-0137 refers to Zinplava (bezlotoxumab), an FDA-approved monoclonal antibody indicated to reduce the recurrence of Clostridioides difficile infection (CDI) in adult patients at high risk for recurrence. The drug was approved in 2016, with notable market entry in hospital settings.
Key Market Drivers for Zinplava
1. Treatment of Recurrent CDI
Zinplava is designed to prevent recurrent CDI, a significant burden in healthcare systems. CDI recurrence rates can reach 20-30% after initial treatment; Zinplava's role is to lower this risk. High-risk populations include elderly patients and those with comorbidities.
2. Market Size and Patient Population
-
U.S. Prevalence: Approximately 453,000 cases annually, with recurrence in roughly 20-30% of cases, translating to 90,600–135,900 high-risk patients per year in the U.S. alone.
-
Global Reach: Primarily used in the U.S., with limited adoption in Europe and other regions due to approval and reimbursement timelines.
3. Competitive Landscape
-
Direct competitors: Fidaxomicin, vancomycin, metronidazole, and newer agents like ridinilazole under development.
-
Positioning: Zinplava is used as adjunct therapy with standard antibiotics, not as standalone. It targets a niche for preventing recurrence rather than initial infection.
Price Analysis
1. Wholesale Acquisition Cost (WAC)
-
The list price for Zinplava is approximately $4,000 to $4,600 per vial in the U.S. (as of 2022-2023). The typical regimen involves two doses of 10 mg/kg, delivered as a single infusion.
-
Treatment course typically involves 2 doses, each costing approximately $4,200 to $4,600, depending on the patient's weight and negotiated discounts.
2. Reimbursement and Payer Coverage
-
Insurance reimbursements vary. Hospitals often negotiate discounts, reducing the effective price paid.
-
Medicare and Medicaid cover Zinplava, with coding under Medicare Part B. The average reimbursement rate often lowers the list price by 10-20%.
3. Market Revenue Estimates
-
2022 Revenue: Estimated between $200 million and $300 million globally, dominated by U.S. sales.
-
Projected Growth: With increased awareness and payer coverage, annual sales could reach $400 million by 2025. Growth is constrained by reimbursement policies, hospitalization rates, and competition.
Price Trends and Future Outlook
-
Pricing Trends: ZInplava's price has remained relatively stable since approval, with some discounts factored into negotiated payer contracts.
-
Potential Price Changes: As biosimilars are not yet on the market, significant downward pressure on price in the near-term is unlikely.
-
Market Expansion: Limited to high-risk recurrent cases in hospital settings. Broader outpatient use depends on evolving guidelines and cost-effectiveness evaluations.
Summary Table
| Aspect |
Detail |
| Approved Since |
2016 |
| Indication |
Preventing recurrence of CDI |
| Typical Dose |
10 mg/kg (two doses) |
| List Price per Dose |
~$4,200–$4,600 |
| Estimated 2022 Revenue |
$200 million – $300 million |
| Projected 2025 Revenue |
Up to $400 million |
| Competitive Landscape |
Fidaxomicin, vancomycin, emerging therapies |
Key Takeaways
- Zinplava targets a specific niche with limited but high-value openings.
- Pricing remains high at roughly $4,200 per dose, with limited pressure for reductions.
- Revenue growth depends on expanding payer coverage and decreasing hospital readmission rates.
- Competition from other CDI therapies constrains potential market share expansion.
- Broader adoption hinges on evidence supporting cost-effectiveness over standard therapies.
FAQs
1. What factors influence the pricing of Zinplava?
Pricing reflects manufacturing costs, development expenses, market positioning, competitive landscape, and payer negotiations. List prices are set high but often discounted in practice.
2. How does Zinplava’s reimbursement compare to its list price?
Reimbursements usually cover 80–90% of the list price after contractual discounts, varying by institution and insurer.
3. What is the potential impact of biosimilars on Zinplava prices?
There are no biosimilars currently approved, but entry of biosimilars usually reduces prices by 20-30% over time, influencing market dynamics.
4. Is there geographic variation in pricing?
Yes. Prices are generally lower outside the U.S. due to government-negotiated rates, differing healthcare policies, and lower drug development costs.
5. What future market developments could affect Zinplava’s pricing or sales?
Introduction of new therapies, expanded indications, better preventive protocols, and developed biosimilars can impact sales and pricing strategies.
Citations
[1] FDA. Zinplava (bezlotoxumab) prescribing information, 2016.
[2] IQVIA. Pharmaceutical Market Data, 2022.
[3] Medicare Provider Payment Data.
[4] Published industry reports on CDI market size and competitive analysis.
